Given that MEK/ERK pathway plays a crucial role in the survival, development, gemcitabine resistance and ERRα-promoted progression of PC 10, 36, 37, we explored whether it is involved in the effectiveness of gemcitabine and XCT790 in PC. The gene discussed is MAP2K7; the disease is pachyonychia congenita.